Related Experiment Videos
Jean-Emmanuel Kurtz1, Véronique D'Hondt2, Fabrice Lécuru3
1Service d'oncologie et d'hématologie, hôpitaux universitaires de Strasbourg, 1, avenue Molière, 67098 Strasbourg, France.
Bulletin Du Cancer
|June 20, 2017
Summary
Treatment for metastatic or recurrent cervical cancer is challenging due to poor chemosensitivity. Platinum-based chemotherapy combined with bevacizumab shows efficacy but requires multidisciplinary tumor board discussion for complex cases.
Area of Science:
- Oncology
- Gynecologic Oncology
Background:
- Metastatic or recurrent cervical cancer has a poor prognosis.
- Chemosensitivity is a significant challenge, particularly after radiation therapy.
- Platinum-based doublets are a common chemotherapy regimen.
Purpose of the Study:
- To review the current treatment strategies for metastatic or recurrent cervical cancer.
- To highlight the efficacy of adding bevacizumab to chemotherapy.
- To emphasize the need for multidisciplinary tumor board evaluation.
Main Methods:
- Literature review of current treatment guidelines and clinical trials.
- Analysis of chemotherapy regimens, including platinum-based doublets.
- Evaluation of the role of bevacizumab in cervical cancer treatment.
Main Results:
- Chemotherapy, primarily platinum-based doublets, demonstrates some efficacy.
- Addition of bevacizumab to chemotherapy has been validated as a treatment option.
- Complex patient cases necessitate comprehensive, multidisciplinary management.
Conclusions:
- Despite challenges, chemotherapy remains a key treatment modality for advanced cervical cancer.
- Bevacizumab offers a promising addition to standard chemotherapy.
- Multidisciplinary tumor boards are crucial for optimizing treatment plans in complex cervical cancer cases.